Literature DB >> 27853831

Role of the lipid-regulated NF-κB/IL-6/STAT3 axis in alpha-naphthyl isothiocyanate-induced liver injury.

Zhong-Ze Fang1,2,3,4,5, Naoki Tanaka2,6, Dan Lu3, Chang-Tao Jiang2, Wei-Hua Zhang7, Chunze Zhang7, Zuo Du1, Zhi-Wei Fu1, Peng Gao5,8, Yun-Feng Cao4,5, Hong-Zhi Sun4,5, Zhi-Tu Zhu4,5, Yan Cai2, Kristopher W Krausz2, Zhi Yao9, Frank J Gonzalez10.   

Abstract

Alpha-naphthyl isothiocyanate (ANIT)-induced liver damage is regarded as a useful model to study drug-induced cholestatic hepatitis. Ultra-performance liquid chromatography coupled with electrospray ionization quadrupole mass spectrometry (UPLC-ESI-QTOF MS)-based metabolomics revealed clues to the mechanism of ANIT-induced liver injury, which facilitates the elucidation of drug-induced liver toxicity. 1-Stearoyl-2-hydroxy-sn-glycero-3-phosphocholine (LPC 18:0) and 1-oleoyl-2-hydroxy-sn-glycero-3-phosphocholine (LPC 18:1) were significantly increased in serum from ANIT-treated mice, and this increase resulted from altered expression of genes encoding the lipid metabolism enzymes Chka and Scd1. ANIT also increased NF-κB/IL-6/STAT3 signaling, and in vitro luciferase reporter gene assays revealed that LPC 18:0 and LPC 18:1 can activate NF-κB in a concentration-dependent manner. Activation of PPARα through feeding mice a Wy-14,643-containing diet (0.1%) reduced ANIT-induced liver injury, as indicated by lowered ALT and AST levels, and liver histology. In conclusion, the present study demonstrated a role for the lipid-regulated NF-κB/IL-6/STAT3 axis in ANIT-induced hepatotoxicity, and that PPARα may be a potential therapeutic target for the prevention of drug-induced cholestatic liver injury.

Entities:  

Keywords:  Alpha-naphthyl isothiocyanate; Drug toxicity; Metabolomics; NF-κB/IL-6/STAT3 axis

Mesh:

Substances:

Year:  2016        PMID: 27853831      PMCID: PMC6331015          DOI: 10.1007/s00204-016-1877-6

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  8 in total

1.  Celastrol Protects From Cholestatic Liver Injury Through Modulation of SIRT1-FXR Signaling.

Authors:  Qi Zhao; Fang Liu; Yan Cheng; Xue-Rong Xiao; Dan-Dan Hu; Ying-Mei Tang; Wei-Min Bao; Jin-Hui Yang; Tao Jiang; Jia-Peng Hu; Frank J Gonzalez; Fei Li
Journal:  Mol Cell Proteomics       Date:  2019-01-07       Impact factor: 5.911

2.  Impaired clearance of sunitinib leads to metabolic disorders and hepatotoxicity.

Authors:  Qi Zhao; Ting Zhang; Xue-Rong Xiao; Jian-Feng Huang; Yan Wang; Frank J Gonzalez; Fei Li
Journal:  Br J Pharmacol       Date:  2019-05-07       Impact factor: 8.739

3.  Inhibition of JNK signalling mediates PPARα-dependent protection against intrahepatic cholestasis by fenofibrate.

Authors:  Manyun Dai; Julin Yang; Minzhu Xie; Jiao Lin; Min Luo; Huiying Hua; Gangming Xu; Hante Lin; Danjun Song; Yuqing Cheng; Bin Guo; Jinshun Zhao; Frank J Gonzalez; Aiming Liu
Journal:  Br J Pharmacol       Date:  2017-08-10       Impact factor: 8.739

4.  Integrated Lipidomics and Metabolomics Study of Four Chemically Induced Mouse Models of Acute Intrahepatic Cholestasis.

Authors:  Weiwei Li; Hui Chen; Yihan Qian; Shouchuan Wang; Zichen Luo; Jinjun Shan; Xiaoni Kong; Yueqiu Gao
Journal:  Front Pharmacol       Date:  2022-06-08       Impact factor: 5.988

Review 5.  Molecular mechanism and research progress on pharmacology of traditional Chinese medicine in liver injury.

Authors:  Hong Yang Zhang; Hong Ling Wang; Guo Yue Zhong; Ji Xiao Zhu
Journal:  Pharm Biol       Date:  2018-12       Impact factor: 3.503

6.  PPARα activation protects against cholestatic liver injury.

Authors:  Qi Zhao; Rui Yang; Jing Wang; Dan-Dan Hu; Fei Li
Journal:  Sci Rep       Date:  2017-08-30       Impact factor: 4.379

7.  Genetic polymorphisms in PXR and NF-κB1 influence susceptibility to anti-tuberculosis drug-induced liver injury.

Authors:  Jingwei Zhang; Zhenzhen Zhao; Hao Bai; Minjin Wang; Lin Jiao; Wu Peng; Tao Wu; Tangyuheng Liu; Hao Chen; Xingbo Song; Lijuan Wu; Xuejiao Hu; Qian Wu; Juan Zhou; Jiajia Song; Mengyuan Lyv; Binwu Ying
Journal:  PLoS One       Date:  2019-09-06       Impact factor: 3.240

8.  Novel roles of lipopolysaccharide and TLR4/NF-κB signaling pathway in inflammatory response to liver injury in Budd-Chiari syndrome.

Authors:  Jie Li; Xiao-Ming Chen; Chun-Ze Zhou; Wei-Wei Fang; Wei-Fu Lv; De-Lei Cheng
Journal:  World J Gastrointest Surg       Date:  2021-11-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.